The Centers for Medicare and Medicaid Services (CMS) New Technology Add-on Payment (NTAP) program provides the opportunity for additional Medicare reimbursement for qualifying innovations. Securing NTAP status helps hospitals use new technologies for their patients by offsetting a portion of the technology’s costs during the early years of commercialization.
In this second installment of our NTAP +Insight series, we’re highlighting key trends and recent growth. The NTAP program saw a fivefold increase in approvals from FY 2018 to FY 2025, driven by high-cost specialty drugs (like CAR-T therapies) and cutting-edge tools (like AI diagnostics). Claims paid under NTAP rose nearly 80% from FY 2019 to FY 2024, yet NTAP claims still made up less than 1% of total Medicare inpatient discharges during this time. Read on as we explore the changing NTAP landscape and its implications for manufacturers and providers.
Visit our Navigating the NTAP Process page to read every article in our NTAP series, get answers to FAQs, and more.
